©The Author(s) 2022.
World J Gastroenterol. Apr 21, 2022; 28(15): 1574-1587
Published online Apr 21, 2022. doi: 10.3748/wjg.v28.i15.1574
Published online Apr 21, 2022. doi: 10.3748/wjg.v28.i15.1574
Table 3 Treatment of recurrent intrahepatic cholangiocarcinoma
| Treatment | n | Median DFS, mo (range) | MS after recurrence, mo (range) |
| Local therapy | 14 | 6 (1-86) | 3 (1-36) |
| Hepatectomy | 2 | 10 (7-13) | 25 (13-36) |
| TACE | 8 | 3 (1-23) | 2 (1-7) |
| RFA | 4 | 7 (2-86) | 3 (1-7) |
| Systemic therapy | 22 | 5 (1-29) | 4 (1-38) |
| Chemotherapy | 3 | 11 (10-29) | 4 (1-38) |
| Targeted therapy | 12 | 3 (1-23) | 4 (1-10) |
| Targeted + immunization therapy | 7 | 4 (1-13) | 7 (2-24) |
| Multimodality therapy | 6 | 4 (2-11) | 7 (4-24) |
| Best supportive care | 12 | 6 (3-20) | 1 (1-6) |
- Citation: Yuan ZB, Fang HB, Feng QK, Li T, Li J. Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study. World J Gastroenterol 2022; 28(15): 1574-1587
- URL: https://www.wjgnet.com/1007-9327/full/v28/i15/1574.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i15.1574